Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Buy” by Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been given an average rating of “Buy” by the five ratings firms that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $11.25.

A number of research analysts have recently issued reports on the stock. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research note on Friday. They issued a “buy” rating and a $7.00 target price for the company. EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Finally, Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Friday.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the period. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Trading Up 0.5 %

NASDAQ RVPH opened at $1.88 on Friday. The stock’s 50 day moving average is $1.56 and its two-hundred day moving average is $1.29. The company has a market capitalization of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a 1-year low of $0.60 and a 1-year high of $4.83.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.